DABIGATRAN ETEXILATE MESYLATE
| Brand name | PRADAXA |
|---|---|
| Active ingredient | DABIGATRAN ETEXILATE MESYLATE |
| Strength | EQ 75MG BASE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | October 2010 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9034822*PED | July 2031 | — |
| 9034822 | January 2031 | use U-1759 |
| 7932273*PED | March 2026 | — |
| 7932273 | September 2025 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.